<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364504</url>
  </required_header>
  <id_info>
    <org_study_id>49RC17_0063</org_study_id>
    <nct_id>NCT03364504</nct_id>
  </id_info>
  <brief_title>Biological Collection of Kidney Cells</brief_title>
  <acronym>CRHiPS</acronym>
  <official_title>Biological Collection of Renal Cells for the Functional Study of the ABCC6 Transporter on iPS-derived Hepatocytes and Renal Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Nantes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hungarian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our objective is to obtain human induced pluripotent stem cells from urine samples of PXE
      patients for further proteomic and metabolomic studies and treatment screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pseudoxanthoma elasticum (PXE) is a genetic multysystem disorder with cutaneous,
      ophtalmological and cardiovascular involvement.

      PXE is associated with mutations of ABCC6 gene coding for the membrane transporter ABCC6
      protein. This transporter is normally expressed in hepatocytes and epithelial cells of renal
      proximal convoluted tubules.

      Thus, PXE could be regarded as a metabolic disease of hepatic and renal origin, with clinical
      and biological involvement/consequences for remote organs.

      The substance transported by ABCC6 protein being still unknown, ethiological PXE treatment
      does not exist yet. However, ABCC6 deficiency is associated with low level of blood PPi
      (pyrophosphate), which is natural inhibitor of calcium-phosphate deposition.

      The aim of the project is to obtain the renal cells derived from PXE patients for their
      further usage in proteomic and metabolomic studies, as well as for screening of treatment
      modalities aimed to correct ABCC6 functional deficiency.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine collection</measure>
    <time_frame>24 hours</time_frame>
    <description>Three urine samples in each PXE in-patient consequences of the functional deficiency of the ABCC6 transporter involved in the pathophysiology of PXE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Isolation and culture of renal cells</measure>
    <time_frame>8 weeks</time_frame>
    <description>According to the routine procedure of our lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of ABCC6 mutations on renal cell functions</measure>
    <time_frame>3 months</time_frame>
    <description>Proteomic and metabolomic and RNAseq approaches</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High throughput screening of drugs to restore ABCC6 function in PXE patients renal cells</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of PPi release and other relevant readouts</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pseudoxanthoma Elasticum</condition>
  <arm_group>
    <arm_group_label>PXE patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>urine collection and culture of renal cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>urine collection</intervention_name>
    <description>3 urine collections during 24 hours</description>
    <arm_group_label>PXE patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with PXE diagnosed on clinical and histological criteria, according to current
             guidelines

          -  Patient aged over 18

          -  Patient informed, having understood the purpose and means of the study and signed the
             consent of participation

          -  Patient affiliated to the French social welfare system

        Exclusion Criteria:

          -  Pregnant or nursing PXE woman

          -  Patient under guardianship, deprived of liberty by court or administrative decision,
             hospitalized without consent or admitted to a health or social institution for
             purposes other than research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Si-Tayeb K, Idriss S, Champon B, Caillaud A, Pichelin M, Arnaud L, Lemarchand P, Le May C, Zibara K, Cariou B. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Dis Model Mech. 2016 Jan;9(1):81-90. doi: 10.1242/dmm.022277. Epub 2015 Nov 19.</citation>
    <PMID>26586530</PMID>
  </results_reference>
  <results_reference>
    <citation>Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. J Med Genet. 2005 Dec;42(12):881-92. Epub 2005 May 13. Review.</citation>
    <PMID>15894595</PMID>
  </results_reference>
  <results_reference>
    <citation>Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Váradi A, Plomp A, Bergen AA, Oude Elferink RP, Borst P, van de Wetering K. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1985-9. doi: 10.1161/ATVBAHA.114.304017. Epub 2014 Jun 26.</citation>
    <PMID>24969777</PMID>
  </results_reference>
  <results_reference>
    <citation>Jansen RS, Küçükosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman IE, Bergen AA, Gorgels TG, Borst P, van de Wetering K. ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20206-11. doi: 10.1073/pnas.1319582110. Epub 2013 Nov 25.</citation>
    <PMID>24277820</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PXE</keyword>
  <keyword>renal cells</keyword>
  <keyword>urine</keyword>
  <keyword>calcification</keyword>
  <keyword>omics</keyword>
  <keyword>drug screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoxanthoma Elasticum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

